Literature DB >> 23692813

International variation in physicians' attitudes towards prophylactic mastectomy - comparison between France, Germany, the Netherlands and the United Kingdom.

M Den Heijer1, C J van Asperen, H Harris, I Nippert, J Schmidtke, A D Bouhnik, C Julian-Reynier, D G Evans, A Tibben.   

Abstract

PURPOSE: Prophylactic mastectomy (PM) has proven to be the most effective method to reduce the risk of breast cancer in high-risk women. The present study aimed to present and compare the attitudes towards PM among physicians in France, Germany, the Netherlands and the United Kingdom (UK). PATIENTS AND METHODS: An international sample of 1196 general practitioners (GPs) and 927 breast surgeons (BS) were surveyed using a mailed questionnaire.
RESULTS: Only 30% of the French and 27% of the German GPs were of opinion that PM should be an option for an unaffected female BRCA1/2 mutation carrier, as compared to 85% and 92% of the GPs in the Netherlands and UK, respectively. Similarly, 78% of the French and 66% of the German BS reported a positive attitude towards PM, as compared to 100% and 97% of the BS in the Netherlands and UK, respectively. In the whole sample of GPs, a positive attitude towards PM was associated with country of residence, being female, and having more knowledge of breast/ovarian cancer genetics, while among BS there was a positive association with country of residence and having more knowledge of breast/ovarian cancer genetics as well, and, in addition, with a higher number of newly diagnosed breast cancer patients last year.
CONCLUSION: These results demonstrated the international variations in the attitude towards PM among physicians. This might reflect that different policies are adopted to prevent breast cancer in women at-risk.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; France; Germany; International variation; Physicians’ attitudes; Prophylactic mastectomy; Surgeons; The Netherlands; The UK

Mesh:

Substances:

Year:  2013        PMID: 23692813     DOI: 10.1016/j.ejca.2013.04.025

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  12 in total

1.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

2.  "Would you test your children without their consent?" and other sticky dilemmas in the field of cancer genetic testing.

Authors:  Karina L Brierley; Danielle C Bonadies; Anne Moyer; Ellen T Matloff
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

3.  Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities.

Authors:  Irmgard Nippert; Claire Julian-Reynier; Hilary Harris; Gareth Evans; Christi J van Asperen; Aad Tibben; Jörg Schmidtke
Journal:  J Community Genet       Date:  2013-12-03

4.  Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England.

Authors:  N N Basu; S Littlechild; L Barr; G L Ross; D G Evans
Journal:  Ann R Coll Surg Engl       Date:  2016-01-07       Impact factor: 1.891

5.  General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profiles.

Authors:  Claire Julian-Reynier; Anne-Deborah Bouhnik; D Gareth Evans; Hilary Harris; Christi J van Asperen; Aad Tibben; Joerg Schmidtke; Irmgard Nippert
Journal:  BMC Cancer       Date:  2015-04-09       Impact factor: 4.430

6.  Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.

Authors:  Anne-Deborah Bouhnik; Khadim N'Diaye; D Gareth Evans; Hilary Harris; Aad Tibben; Christi van Asperen; Joerg Schmidtke; Irmgard Nippert; Julien Mancini; Claire Julian-Reynier
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

7.  International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Authors:  Kelly Metcalfe; Andrea Eisen; Leigha Senter; Susan Armel; Louise Bordeleau; Wendy S Meschino; Tuya Pal; Henry T Lynch; Nadine M Tung; Ava Kwong; Peter Ainsworth; Beth Karlan; Pal Moller; Charis Eng; Jeffrey N Weitzel; Ping Sun; Jan Lubinski; Steven A Narod
Journal:  Br J Cancer       Date:  2019-04-11       Impact factor: 7.640

8.  Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

Authors:  D Gareth Evans; Sacha J Howell; Anthony Howell
Journal:  Fam Cancer       Date:  2019-10       Impact factor: 2.375

9.  Physicians' attitudes and knowledge concerning antibiotic prescription and resistance: questionnaire development and reliability.

Authors:  António Teixeira Rodrigues; Mónica Ferreira; Fátima Roque; Amílcar Falcão; Elmano Ramalheira; Adolfo Figueiras; Maria Teresa Herdeiro
Journal:  BMC Infect Dis       Date:  2016-01-08       Impact factor: 3.090

10.  Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives.

Authors:  Pierre Vande Perre; Daniel Toledano; Carole Corsini; Elsa Escriba; Marine Laporte; Helena Bertet; Kevin Yauy; Alain Toledano; Virginie Galibert; Karen Baudry; Lucie Clotet; Elodie Million; Marie-Christine Picot; David Geneviève; Pascal Pujol
Journal:  Mol Genet Genomic Med       Date:  2018-10-11       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.